Search results for "Breast"

showing 10 items of 1871 documents

miR-9 and miR-200 regulate PDGFRβ-mediated endothelial differentiation of tumor cells in triple-negative breast cancer

2016

Abstract Organization of cancer cells into endothelial-like cell-lined structures to support neovascularization and to fuel solid tumors is a hallmark of progression and poor outcome. In triple-negative breast cancer (TNBC), PDGFRβ has been identified as a key player of this process and is considered a promising target for breast cancer therapy. Thus, we aimed at investigating the role of miRNAs as a therapeutic approach to inhibit PDGFRβ-mediated vasculogenic properties of TNBC, focusing on miR-9 and miR-200. In MDA-MB-231 and MDA-MB-157 TNBC cell lines, miR-9 and miR-200 promoted and inhibited, respectively, the formation of vascular-like structures in vitro. Induction of endogenous miR-9…

0301 basic medicinePathologymedicine.medical_specialtyCancer ResearchCellular differentiationBlotting WesternFluorescent Antibody TechniqueTriple Negative Breast NeoplasmsMice SCIDBiologySettore MED/08 - Anatomia PatologicaPolymerase Chain ReactionNeovascularizationReceptor Platelet-Derived Growth Factor beta03 medical and health sciencesMice0302 clinical medicinemicroRNAmedicineAnimalsHumansTriple-negative breast cancerIn Situ HybridizationRegulation of gene expressionNeovascularization PathologicCancerEndothelial CellsCell Differentiationmedicine.diseaseImmunohistochemistryGene Expression Regulation NeoplasticMicroRNAs030104 developmental biologyOncologyOncology; Cancer Research030220 oncology & carcinogenesisGene Knockdown TechniquesCancer cellCancer researchHeterograftsEctopic expressionFemalemedicine.symptom
researchProduct

Molecular alterations in lesions of anogenital mammary-like glands and their mammary counterparts including hidradenoma papilliferum, intraductal pap…

2017

Lesions affecting anogenital mammary-like glands (AGMLG) are histopathologically very similar to those seen in the breast but whether this morphological similarity is also reflected at the genetic level is unknown. To compare the underlying molecular mechanisms in lesions of AGMLG and their mammary counterparts, we analyzed the mutational profile of 16 anogenital neoplasms including 5 hidradenomas papilliferum (HP), 1 lesion with features of HP and fibroadenoma (FA), 7 FA, 3 phyllodes tumors (PhT)) and 18 analogous breast lesions (6 intraductal papillomas (IDP), 9 FA, and 3 PhT) by high-coverage next generation sequencing (NGS) using a panel comprising 50 cancer-related genes. Additionally,…

0301 basic medicinePathologymedicine.medical_specialtyHidradenomaClass I Phosphatidylinositol 3-KinasesBreast NeoplasmsBiologyPathology and Forensic MedicineVulvaMED12Papilloma IntraductalLesionPhosphatidylinositol 3-Kinases03 medical and health sciencessymbols.namesake0302 clinical medicinePhyllodes TumorIntraductal papillomamedicineHumansBreastAgedSanger sequencingVulvar NeoplasmsHigh-Throughput Nucleotide SequencingPhyllodes tumorGeneral MedicineMiddle Agedmedicine.diseaseFibroadenomaTubular Sweat Gland Adenomas030104 developmental biologymedicine.anatomical_structureFibroadenoma030220 oncology & carcinogenesisMutationsymbolsFemalemedicine.symptomAnnals of Diagnostic Pathology
researchProduct

A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma.

2017

IF 1.590; International audience; Background: The tumor spectrum in the Lynch syndrome is well defined, comprising an increased risk of developing colonic and extracolonic malignancies. Muir-Torre syndrome is a variant with a higher risk of skin disease. Patients have been described carrying mutations in the mismatch repair genes and presenting tumors with unusual histology or affected organ not part of the Lynch syndrome spectrum. Hence, the real link between Lynch syndrome, or Muir-Torre syndrome, and these tumors remains difficult to assess.Case presentation: We present the case of a 45-year-old-woman, diagnosed with breast cancer at 39 years of age and skin squamous cell carcinoma (SCC)…

0301 basic medicinePathologymedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitieslcsh:QH426-470Case Report[SDV.CAN]Life Sciences [q-bio]/CancerMLH1lcsh:RC254-282Sebaceous adenoma[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineSebaceous adenomaBreast cancerMuir–Torre syndromeSquamous cell carcinomaPMS2Skin Squamous Cell CarcinomaMedicineneoplasmsGenetics (clinical)MSIbusiness.industryMicrosatellite instabilitynutritional and metabolic diseasesMuir-Torre syndromeMSI-Llcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMMRLynch syndromedigestive system diseases3. Good healthMSH2lcsh:Genetics030104 developmental biologyLynch syndromeOncologyMSH2030220 oncology & carcinogenesisCancer researchbusiness
researchProduct

A multiomics analysis of S100 protein family in breast cancer

2018

The S100 gene family is the largest subfamily of calcium binding proteins of EF-hand type, expressed in tissue and cell-specific manner, acting both as intracellular regulators and extracellular mediators. There is a growing interest in the S100 proteins and their relationships with different cancers because of their involvement in a variety of biological events closely related to tumorigenesis and cancer progression. However, the collective role and the possible coordination of this group of proteins, as well as the functional implications of their expression in breast cancer (BC) is still poorly known. We previously reported a large-scale proteomic investigation performed on BC patients f…

0301 basic medicinePathway analysiBiologyProteomicsmedicine.disease_causeBreast cancer; Expression analysis; Pathway analysis; Proteomics; S100 proteins; OncologyTranscriptome03 medical and health sciencesproteomics0302 clinical medicineBreast cancerBreast cancerExpression analysiSettore BIO/13 - Biologia ApplicataCalcium-binding proteinmedicineGene familyexpression analysisSettore BIO/06 - Anatomia Comparata E CitologiaCancerProteomicmedicine.diseasePhenotypepathway analysisS100 proteinSettore BIO/18 - Genetica030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchCarcinogenesisS100 proteinsResearch Paper
researchProduct

Maternal Diet and Nutrient Requirements in Pregnancy and Breastfeeding. An Italian Consensus Document.

2016

The importance of lifestyle and dietary habits during pregnancy and breastfeeding, for health of mothers and their offspring, is widely supported by the most recent scientific literature. The consumption of a varied and balanced diet from the preconceptional period is essential to ensure both maternal well-being and pregnancy outcomes. However, the risk of inadequate intakes of specific micronutrients in pregnancy and lactation is high even in the most industrialized countries. This particularly applies to docosahexaenoic acid (DHA), iron, iodine, calcium, folic acid, and vitamin D, also in the Italian population. Moreover, the risk of not reaching the adequate nutrient supply is increased …

0301 basic medicinePediatricsmedicine.medical_specialtyConsensusOffspringbreastfeedingBreastfeedingMotherslcsh:TX341-641ReviewOverweight03 medical and health sciencesEnvironmental healthHumansMedicinemicronutrientPregnancynutrient requirement030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryNutritional RequirementsFeeding BehaviorMaternal Nutritional Physiological Phenomenaadequate intakemedicine.diseaseMicronutrientDietDHABreast FeedingHuman nutritionItalyDietary Reference IntakemicronutrientsFemalepregnancymedicine.symptomUnderweightbusinesslcsh:Nutrition. Foods and food supplyFood Science
researchProduct

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

2017

Summary Most patients with advanced triple-negative breast cancer (TNBC) develop drug resistance. MYC and MCL1 are frequently co-amplified in drug-resistant TNBC after neoadjuvant chemotherapy. Herein, we demonstrate that MYC and MCL1 cooperate in the maintenance of chemotherapy-resistant cancer stem cells (CSCs) in TNBC. MYC and MCL1 increased mitochondrial oxidative phosphorylation (mtOXPHOS) and the generation of reactive oxygen species (ROS), processes involved in maintenance of CSCs. A mutant of MCL1 that cannot localize in mitochondria reduced mtOXPHOS, ROS levels, and drug-resistant CSCs without affecting the anti-apoptotic function of MCL1. Increased levels of ROS, a by-product of a…

0301 basic medicinePhysiologyMice NudeTriple Negative Breast NeoplasmsOxidative phosphorylationTumor initiationMitochondrionBiologyOxidative PhosphorylationArticleProto-Oncogene Proteins c-myc03 medical and health sciencesCancer stem cellCell Line TumorAnimalsHumansMCL1Molecular BiologyTriple-negative breast cancerchemistry.chemical_classificationReactive oxygen speciesCell BiologyMitochondria030104 developmental biologychemistryDrug Resistance NeoplasmNeoplastic Stem CellsCancer researchMyeloid Cell Leukemia Sequence 1 ProteinFemaleStem cellReactive Oxygen SpeciesCell Metabolism
researchProduct

“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors

2017

Several evidences have shown that BRCA mutations increased tumor-cells sensitivity to PARP inhibitors by synthetic lethality leading to an accelerated development of several compounds targeting the PARP enzymes system as anticancer agents for clinical setting. Most of such compounds have been investigated in ovarian and breast cancer, showing promising efficacy in BRCA-mutated patients. Recently clinical studies of PARP-inhibitors have been extended across different tumor types harboring BRCA-mutations, including also "BRCA-like" sporadic tumors with homologous recombination deficiency (HRD). This review summarizes the biological background underlying PARP-inhibition, reporting the results …

0301 basic medicinePoly ADP ribose polymerasemedicine.medical_treatmentReviewSynthetic lethalityPoly(ADP-ribose) Polymerase Inhibitorsmedicine.disease_causePoly (ADP-Ribose) Polymerase Inhibitorresistance03 medical and health sciences0302 clinical medicineBreast cancerCell Line TumorBRCA1-2AnimalsHumansMedicinePARP inhibitorsBRCA2 ProteinGeneticsMutationChemotherapyBRCA1 Proteinbusiness.industryBRCA1-2; PARP inhibitors; Resistance; Oncologymedicine.diseaseBRCA2 ProteinClinical trialPARP inhibitor030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisMutationCancer researchbusinessOncotarget
researchProduct

Anticancer activity of biogenerated silver nanoparticles: an integrated proteomic investigation

2018

Silver nanoparticles (AgNPs), embedded into a specific polysaccharide (EPS), were biogenerated by Klebsiella oxytoca DSM 29614 under aerobic (AgNPs-EPSaer) and anaerobic conditions (AgNPs-EPSanaer). Both AgNPs-EPS matrices were tested by MTT assay for cytotoxic activity against human breast (SKBR3 and 8701-BC) and colon (HT-29, HCT 116 and Caco-2) cancer cell lines, revealing AgNPs-EPSaer as the most active, in terms of IC50, with a more pronounced efficacy against breast cancer cell lines. Therefore, colony forming capability, morphological changes, generation of reactive oxygen species (ROS), induction of apoptosis and autophagy, inhibition of migratory and invasive capabilities and prote…

0301 basic medicineProgrammed cell deathSettore BIO/11 - Biologia MolecolareMitochondrionmedicine.disease_causeSettore BIO/19 - Microbiologia Generale03 medical and health sciencesproteomicsbreast cancer cellmedicineMTT assaySettore BIO/06 - Anatomia Comparata E Citologiabacteriachemistry.chemical_classificationAnticancer activity; Bacteria; Breast cancer cells; Proteomics; Silver nanoparticles (AgNPs); OncologyReactive oxygen speciesBreast cancer cellsChemistryAutophagysilver nanoparticles (AgNPs)Cell biology030104 developmental biologyanticancer activitysilver nanoparticles (AgNPs); bacteria; breast cancer cells; anticancer activity; proteomicsOncologyApoptosisSKBR3Oxidative stressResearch Paper
researchProduct

MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection.

2018

Abstract To build a catalog of peptides presented by breast cancer cells, we undertook systematic MHC class I immunoprecipitation followed by elution of MHC class I-loaded peptides in breast cancer cells. We determined the sequence of 3196 MHC class I ligands representing 1921 proteins from a panel of 20 breast cancer cell lines. After removing duplicate peptides, i.e., the same peptide eluted from more than one cell line, the total number of unique peptides was 2740. Of the unique peptides eluted, more than 1750 had been previously identified, and of these, sixteen have been shown to be immunogenic. Importantly, half of these immunogenic peptides were shared between different breast cancer…

0301 basic medicineProteomicsPlant BiologyPeptideLigandsBiochemistryEpitopeAnalytical ChemistryEpitopesBreast cancerT cell-mediated immune responseHLA Antigens2.1 Biological and endogenous factorsAetiologyCancerchemistry.chemical_classificationAntigen PresentationTumorbiologyBiochemistry & Molecular BiologyBiophysicsBreast NeoplasmsArticleCell LineVaccine Related03 medical and health sciencesImmune systemBreast cancerAntigenAntigens NeoplasmCell Line TumorMHC class ImedicineGeneticsHumansAmino Acid SequenceAntigensMHC class I-restricted peptidesTumor associated antigensPreventionHistocompatibility Antigens Class ICancermedicine.diseaseHigh-Throughput Screening Assays030104 developmental biologychemistryCell cultureNeo-antigensMutationbiology.proteinCancer researchNeoplasmImmunizationBiochemistry and Cell Biology
researchProduct

Cytotoxic activity of the histone deacetylase 3-Selective inhibitor Pojamide on MDA-MB-231 triple-negative breast cancer cells

2019

We examined the effects of the ferrocene-based histone deacetylase-3 inhibitor Pojamide (N1-(2-aminophenyl)-N8-ferrocenyloctanediamide) and its two derivatives N1-(2-aminophenyl)-N6-ferrocenyladipamide and N1-(2-aminophenyl)-N8-ferroceniumoctanediamide tetrafluoroborate on triple-negative MDA-MB-231 breast cancer cells. Viability/growth assays indicated that only the first two compounds at 70 &mu

0301 basic medicineQD0901Triple Negative Breast Neoplasmslcsh:Chemistry0302 clinical medicinebreast cancer cellmitochondrial transmembrane potentialCytotoxic T cellQDSettore BIO/06 - Anatomia Comparata E Citologialcsh:QH301-705.5SpectroscopyTriple-negative breast cancerreactive oxygen speciesCell DeathChemistryHistone deacetylase inhibitorQapoptosisGeneral MedicineCell cycle3. Good healthComputer Science Applications030220 oncology & carcinogenesisFemalecell cycleProgrammed cell deathautophagymedicine.drug_classCell SurvivalCatalysisArticleHistone DeacetylasesInorganic Chemistry03 medical and health sciencesCell Line TumormedicineBiomarkers TumorHumansViability assayPhysical and Theoretical ChemistryMolecular Biologyhistone deacetylase inhibitorcell viabilityOrganic ChemistryAutophagyapoptosiMatrix MetalloproteinasesHistone Deacetylase InhibitorsSettore BIO/18 - Genetica030104 developmental biologylcsh:Biology (General)lcsh:QD1-999ApoptosisCancer researchQD0146breast cancer cells
researchProduct